Market Cap
$288.7M
RCKT
ROCKET PHARMACEUTICALS, INC.
$2.57 ▼ -0.97%
Prev close $2.59Market cap$288.7M
ConsensusHold
12-mo target$8.85 (+245.2%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)25 New Institutional Positions22 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on RCKT right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Buy (55%)
Inst. Holders
50 funds
Inst. Value
$294.2M
Inst. Activity
25 buys / 22 sells
Insider Activity
$0.00 buy / $732.9K sell
Insider Net $
-$732.9K
Social Sentiment
77° Bullish
SEC Reports
12
Price chart 30d -33.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Sep 15, 2026 SEC Short Volume: RCKT — 55.6% short (0.6M / 1.2M)
Short: 648,938 | Exempt: 498 | TRF Vol: 1,166,467 | Short Ratio: 55.6% | Off-exchange volume (dark p
Rocket Pharmaceuticals announced FDA alignment on the path to complete the pivotal Phase 2 trial of RP-A501 for Danon di
8-K — Impact 7/10
Sep 11, 2026 Insider
Aug 21, 2026 SEC Wilson Martin sold 75,364 shares
General Counsel @ $3.40 ($256.5K)
Four Rocket Pharmaceuticals insiders, including CEO Gaurav Shah and COO Christopher Stevens, sold a total of $164K in op
CLUSTER — Impact 4/10
Aug 18, 2026 Insider
Wilson Martin sold 631 shares
General Counsel @ $3.38 ($2.1K)
Aug 18, 2026 Insider
Aug 17, 2026 SEC Shah Gaurav sold 2,293 shares
CEO @ $3.38 ($7.8K)
Three Rocket Pharmaceuticals insiders, including the CEO and COO, sold a total of $154K in open-market sales over a 7-da
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
9,923,962 shares ($33.9M)
Analyst ratings buy % -3.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
55% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 16, 2026 | Wedbush | REITERATE | Outperform | 57% |
| Sep 16, 2026 | Needham | UPGRADE | Buy | 50% |
| Sep 15, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Sep 1, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Aug 11, 2026 | Wedbush | MAINTAIN | Outperform | 57% |
| May 11, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Aug 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Jul 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Jun 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| May 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Apr 1, 2026 | 4 | 7 | 7 | 2 | 0 | 55% | |
| Mar 1, 2026 | 5 | 7 | 7 | 2 | 0 | 57% | |
| Feb 1, 2026 | 5 | 7 | 7 | 2 | 0 | 57% |
Price targets
Where 12 covering analysts think RCKT trades over the next 12 months.
$8.85 +245.2% upside Strong Buy
Current$2.57 Low$3.00 Median$9.50 High$15.00 12 analysts
$3.00$15.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
77°
Bullish
BearishNeutralBullish
Recent posts
Rocket Pharmaceuticals 1-2 month outlook? (RCKT)
▲ 1 · 💬 0· ⚡ 0.5
ALGUIEN MAS CON RCKT?
▲ 1 · 💬 1· ⚡ 0.5
Rocket Pharmaceuticals (RCKT) Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
▲ 1 · 💬 1· ⚡ 0.5
Whe The Market Might Rocket Over RCKT
▲ 1 · 💬 0· ⚡ 0.5
Rocket pharmaceuticals gets FDA approval (RCKT)
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 4 bullish, 1 bearish, 0 mixed, 7 neutral · avg impact 4.6/10.
BULLISH8-K7/10
Rocket Pharmaceuticals announced FDA alignment on the path to complete the pivotal Phase 2 trial of
Sep 15, 2026
NEUTRALCLUSTER4/10
Four Rocket Pharmaceuticals insiders, including CEO Gaurav Shah and COO Christopher Stevens, sold a
Aug 21, 2026
NEUTRALCLUSTER4/10
Three Rocket Pharmaceuticals insiders, including the CEO and COO, sold a total of $154K in open-mark
Aug 17, 2026
NEUTRALCLUSTER3/10
Two insiders at Rocket Pharmaceuticals, including the COO, sold a combined $145K in open-market sale
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
short_volume
Short Volume: RCKT — 55.6% short (0.6M / 1.2M)
Short: 648,938 | Exempt: 498 | TRF Vol: 1,166,467 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: RCKT — 56.7% short (0.3M / 0.6M)
Short: 341,761 | Exempt: 0 | TRF Vol: 602,435 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: RCKT — 59.1% short (0.6M / 1.0M)
Short: 574,079 | Exempt: 135 | TRF Vol: 972,006 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: RCKT — 56.7% short (0.7M / 1.2M)
Short: 705,145 | Exempt: 95,169 | TRF Vol: 1,243,720 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: RCKT — 57.6% short (1.5M / 2.6M)
Short: 1,475,262 | Exempt: 261,659 | TRF Vol: 2,559,354 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.41 | $-0.43–$-0.35 | 10.3% | +2.2% | 2↑ 1↓ | $0.0B | 5 |
| Next Q | $-0.41 | $-0.45–$-0.37 | -7.8% | -4.7% | 2↑ 1↓ | $0.0B | 5 |
| Current FY | $-0.11 | $-0.20–$0.08 | 94.6% | +88.0% | 1↑ 0↓ | $0.0B | 4 |
| Next FY | $-1.30 | $-1.84–$-0.12 | -1111.2% | -7.0% | 1↑ 1↓ | $0.0B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.406 | — |
| 7d ago | $-0.406 | — |
| 30d ago | $-0.415 | +0.009 |
| 60d ago | $-0.415 | +0.009 |
| 90d ago | $-0.415 | +0.009 |
Institutional ownership
Which big funds own RCKT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $294.2M total value (86,047,565 shares) as of 2026-Q2. Top holders: RTW, BlackRock,, VANGUARD. Net buying activity: 25 institutions added/increased vs 22 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 17,687,772 | $60.5M | 20.6% | — |
| BlackRock, Inc. | 9,923,962 | $33.9M | 11.5% | ADD +26.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,810,033 | $19.9M | 6.8% | — |
| CITIGROUP INC | 4,865,551 | $16.6M | 5.7% | — |
| MARSHALL WACE, LLP | 4,029,262 | $13.8M | 4.7% | ADD +32.6% |
| MILLENNIUM MANAGEMENT LLC | 4,000,344 | $13.7M | 4.7% | ADD +28.3% |
| MAVERICK CAPITAL LTD | 3,923,963 | $13.4M | 4.6% | ADD +42.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,784,387 | $12.9M | 4.4% | — |
| AQR CAPITAL MANAGEMENT LLC | 3,386,162 | $11.6M | 3.9% | — |
| GOLDMAN SACHS GROUP INC | 2,833,427 | $9.7M | 3.3% | ADD +64.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 7,834,795 | 9,923,962 | +26.7% | $33.9M |
| MARSHALL WACE, LLP | ADD | 3,038,715 | 4,029,262 | +32.6% | $13.8M |
| MILLENNIUM MANAGEMENT LLC | ADD | 3,118,124 | 4,000,344 | +28.3% | $13.7M |
| GOLDMAN SACHS GROUP INC | ADD | 1,721,116 | 2,833,427 | +64.6% | $9.7M |
| FEDERATED HERMES, INC. | DOUBLED | 1,023,747 | 2,304,207 | +125.1% | $7.9M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | DOUBLED | 416,533 | 1,974,896 | +374.1% | $6.8M |
| JPMORGAN CHASE & CO | DOUBLED | 796,224 | 1,988,413 | +149.7% | $6.7M |
| STATE STREET CORP | TRIM | 4,485,989 | 1,820,121 | -59.4% | $6.2M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 288,264 | 1,125,500 | +290.4% | $3.8M |
| MORGAN STANLEY | TRIM | 2,020,108 | 1,062,522 | -47.4% | $3.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$732.9K — $0.00 bought, $732.9K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Wilson Martin | General Counsel | SELL | 75,364 | $3.40 | $256.5K |
| Aug 18, 2026 | Wilson Martin | General Counsel | SELL | 631 | $3.38 | $2.1K |
| Aug 18, 2026 | Shah Gaurav | CEO | SELL | 2,293 | $3.38 | $7.8K |
| Aug 13, 2026 | Shah Gaurav | CEO | SELL | 2,837 | $3.38 | $9.6K |
| Aug 13, 2026 | Wilson Martin | General Counsel | SELL | 3,493 | $3.38 | $11.8K |
| Aug 11, 2026 | Stevens Christopher James | Chief Operating Officer | SELL | 36,658 | $3.50 | $128.3K |
| Aug 11, 2026 | Chaudhuri Sarbani | See Remarks | SELL | 4,701 | $3.50 | $16.4K |
| Aug 3, 2026 | Stevens Christopher James | Chief Operating Officer | AWARD | 73,313 | — | — |
| Aug 3, 2026 | Stevens Christopher James | Chief Operating Officer | AWARD | 101,428 | — | — |
| Aug 3, 2026 | SOUTHWELL DAVID P | Director | J | 150,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RCKT.
Shares short
14,847,478
Settlement Sep 15, 2026
Change vs prior
+0.9%
Semi-monthly cycle
Days to cover
11.1
At avg daily volume
Of shares outstanding
≈13.5%
Estimate — not % of float
All RCKT filing & press-release reports (12)
- 8-K reportSep 15, 2026
- CLUSTER reportAug 21, 2026
- CLUSTER reportAug 17, 2026
- CLUSTER reportAug 14, 2026
- 8-K reportAug 11, 2026
- 8-K reportAug 3, 2026
- 8-K reportJul 3, 2026
- 8-K reportJun 12, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 14, 2026
- EFFECT reportMar 11, 2026
- S-3 reportMar 2, 2026